Influence of Vitamin D and Its Analogues in Type-B Lymphomas.

IF 3.4 4区 医学 Q2 ONCOLOGY Current oncology Pub Date : 2025-02-26 DOI:10.3390/curroncol32030135
Valerio Basile, Alessandro Allegra, Herbert Ryan Marini, Massimiliano Berretta, Barbara Granata, José Freni, Domenico Puzzolo, Fabio Stagno, Paola Midiri, Valentina Urzì Brancati, Letteria Minutoli
{"title":"Influence of Vitamin D and Its Analogues in Type-B Lymphomas.","authors":"Valerio Basile, Alessandro Allegra, Herbert Ryan Marini, Massimiliano Berretta, Barbara Granata, José Freni, Domenico Puzzolo, Fabio Stagno, Paola Midiri, Valentina Urzì Brancati, Letteria Minutoli","doi":"10.3390/curroncol32030135","DOIUrl":null,"url":null,"abstract":"<p><p>Lymphomas represent a heterogeneous group of blood tumors, generally divided into non-Hodgkin lymphoma (NHL) (90% of all lymphomas) and Hodgkin lymphoma (HL). High-grade NHL can rapidly progress so that new strategies and potentially therapeutical options are needed. Recently, it was shown that Vitamin D (VitD) inhibits the growth of cancer cells, controls their invasion and metastasis, and strengthens the antitumor activity of various types of chemotherapeutic anticancer agents. Therefore, we reviewed the recent literature about the influence of VitD and its analogues (VDAs) on the treatment and the prognosis of B-cell lymphomas. As to the in vitro studies in different cell lines, VitD3 and VDAs enhanced the anti-proliferative efficacy of various chemotherapeutics and increased the expression of VitD receptor. In in vivo studies, blood levels of VitD were considered: higher values of plasma bioavailable VitD were correlated with better progression-free survival (PFS) and overall survival (OS), while an unfavorable PFS and OS were observed in VitD deficient groups. No clinical trial was made on the analogs, thus confirming the absence of in vivo positive role of these synthetic drugs. In conclusion, higher levels of circulating VitD are related to improved OS, reduced cancer-specific mortality, and better disease-free survival. VitD and analogs showed also positive effects in in vitro studies, while only VitD was able to improve clinical parameters. Furthermore, a complex approach with plant-based diet, adequate levels for motor exercise, and/or eventual VitD supplementation could be a valuable strategy to challenge lymphomas.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 3","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941339/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32030135","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Lymphomas represent a heterogeneous group of blood tumors, generally divided into non-Hodgkin lymphoma (NHL) (90% of all lymphomas) and Hodgkin lymphoma (HL). High-grade NHL can rapidly progress so that new strategies and potentially therapeutical options are needed. Recently, it was shown that Vitamin D (VitD) inhibits the growth of cancer cells, controls their invasion and metastasis, and strengthens the antitumor activity of various types of chemotherapeutic anticancer agents. Therefore, we reviewed the recent literature about the influence of VitD and its analogues (VDAs) on the treatment and the prognosis of B-cell lymphomas. As to the in vitro studies in different cell lines, VitD3 and VDAs enhanced the anti-proliferative efficacy of various chemotherapeutics and increased the expression of VitD receptor. In in vivo studies, blood levels of VitD were considered: higher values of plasma bioavailable VitD were correlated with better progression-free survival (PFS) and overall survival (OS), while an unfavorable PFS and OS were observed in VitD deficient groups. No clinical trial was made on the analogs, thus confirming the absence of in vivo positive role of these synthetic drugs. In conclusion, higher levels of circulating VitD are related to improved OS, reduced cancer-specific mortality, and better disease-free survival. VitD and analogs showed also positive effects in in vitro studies, while only VitD was able to improve clinical parameters. Furthermore, a complex approach with plant-based diet, adequate levels for motor exercise, and/or eventual VitD supplementation could be a valuable strategy to challenge lymphomas.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
维生素D及其类似物对b型淋巴瘤的影响。
淋巴瘤是一类异质性血液肿瘤,一般分为非霍奇金淋巴瘤(NHL)(占所有淋巴瘤的 90%)和霍奇金淋巴瘤(HL)。高级别 NHL 可以迅速发展,因此需要新的策略和潜在的治疗方案。最近的研究表明,维生素 D(VitD)可抑制癌细胞的生长,控制癌细胞的侵袭和转移,并增强各类抗癌化疗药物的抗肿瘤活性。因此,我们回顾了近期有关维生素 D 及其类似物(VDAs)对 B 细胞淋巴瘤治疗和预后影响的文献。在不同细胞系的体外研究中,VitD3 和 VDAs 增强了各种化疗药物的抗增殖功效,并增加了 VitD 受体的表达。在体内研究中,考虑了血液中的 VitD 水平:血浆中生物可利用的 VitD 值越高,无进展生存期(PFS)和总生存期(OS)就越好,而缺乏 VitD 的组别无进展生存期和总生存期就越差。没有对类似物进行临床试验,因此证实这些合成药物在体内没有积极作用。总之,较高水平的循环 VitD 与改善 OS、降低癌症特异性死亡率和提高无病生存率有关。VitD 和类似物在体外研究中也显示出积极作用,而只有 VitD 能够改善临床参数。此外,以植物为基础的饮食、适量的运动和/或最终补充 VitD 的复合方法可能是挑战淋巴瘤的重要策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current oncology
Current oncology ONCOLOGY-
CiteScore
3.30
自引率
7.70%
发文量
664
审稿时长
1 months
期刊介绍: Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.
期刊最新文献
Assessing Training Practices and Gaps for Staff Involved in the Delivery of Oncology Financial Navigation: A Qualitative Study. Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer. Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT. BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG. CDX2 Expression and Fluoropyrimidine Response in Rare Non-GI Tumors: A Three-Case Series.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1